1. Home
  2. CHRO vs PET Comparison

CHRO vs PET Comparison

Compare CHRO & PET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRO
  • PET
  • Stock Information
  • Founded
  • CHRO 2002
  • PET 2015
  • Country
  • CHRO United States
  • PET United States
  • Employees
  • CHRO N/A
  • PET N/A
  • Industry
  • CHRO
  • PET EDP Services
  • Sector
  • CHRO
  • PET Technology
  • Exchange
  • CHRO Nasdaq
  • PET Nasdaq
  • Market Cap
  • CHRO 8.4M
  • PET 7.4M
  • IPO Year
  • CHRO 2024
  • PET N/A
  • Fundamental
  • Price
  • CHRO $1.14
  • PET $0.14
  • Analyst Decision
  • CHRO Strong Buy
  • PET Strong Buy
  • Analyst Count
  • CHRO 1
  • PET 4
  • Target Price
  • CHRO N/A
  • PET $4.13
  • AVG Volume (30 Days)
  • CHRO 83.2K
  • PET 2.1M
  • Earning Date
  • CHRO 05-13-2025
  • PET 05-12-2025
  • Dividend Yield
  • CHRO N/A
  • PET N/A
  • EPS Growth
  • CHRO N/A
  • PET N/A
  • EPS
  • CHRO N/A
  • PET N/A
  • Revenue
  • CHRO N/A
  • PET $62,453,000.00
  • Revenue This Year
  • CHRO N/A
  • PET $7.87
  • Revenue Next Year
  • CHRO N/A
  • PET $122.23
  • P/E Ratio
  • CHRO N/A
  • PET N/A
  • Revenue Growth
  • CHRO N/A
  • PET N/A
  • 52 Week Low
  • CHRO $0.45
  • PET $0.08
  • 52 Week High
  • CHRO $3.80
  • PET $1.79
  • Technical
  • Relative Strength Index (RSI)
  • CHRO 53.88
  • PET 46.08
  • Support Level
  • CHRO $0.90
  • PET $0.14
  • Resistance Level
  • CHRO $1.06
  • PET $0.17
  • Average True Range (ATR)
  • CHRO 0.09
  • PET 0.01
  • MACD
  • CHRO 0.03
  • PET 0.00
  • Stochastic Oscillator
  • CHRO 95.88
  • PET 21.89

About CHRO Chromocell Therapeutics Corporation

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

About PET Wag! Group Co.

Wag Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent Pet Caregivers to connect with pet parents. The platform allows pet parents to make pet service requests in the platform, which can then be fulfilled by Pet Caregivers. Wag supports dog walking, pet sitting, pet boarding, drop-in visits at the pet parent's home, advice from licensed pet experts, training services, pet insurance comparison tools and pet wellness plans.

Share on Social Networks: